Last reviewed · How we verify
Exantide with Dapagliflozin
Exenatide (a GLP-1 receptor agonist) stimulates insulin secretion and reduces glucagon, while dapagliflozin (an SGLT2 inhibitor) increases urinary glucose excretion, together improving glycemic control through complementary pathways.
Exenatide (a GLP-1 receptor agonist) stimulates insulin secretion and reduces glucagon, while dapagliflozin (an SGLT2 inhibitor) increases urinary glucose excretion, together improving glycemic control through complementary pathways. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Exantide with Dapagliflozin |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | GLP-1 receptor agonist / SGLT2 inhibitor combination |
| Target | GLP-1 receptor; SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Exenatide activates GLP-1 receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion and suppress glucagon release. Dapagliflozin inhibits sodium-glucose cotransporter 2 in the proximal renal tubule, promoting urinary glucose excretion independent of insulin. This dual mechanism addresses hyperglycemia through both insulin-dependent and insulin-independent pathways.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Genital mycotic infections
- Urinary tract infection
- Hypoglycemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |